Karri Alameri OmaSp:n toimitusjohtaja Karri Alameri Jaakko Ossa OmaSp:n hallituksen puheenjohtaja Jaakko Ossa OmaSp konttori OmaSp konttori Turku OMA SAVINGS BANK PLC STOCK EXCHANGE RELEASE, 14 JANUARY 2026 AT 16.20 P.M. EET, OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE Oma Savings Bank Plc’s Growth Strategy for 2026–2029 The Board of Directors of Oma Savings Bank Plc (“OmaSp” or the “Company”) has approved the Company’s strategy and financial targets for the 2026–2029 peri ...

Access the segment here SOUTH SAN FRANCISCO, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Virtual Investor CEO Connect Segment. As part of the segment, Timothy Lu, MD, PhD, CEO of Senti, discussed its recent news release announcing that the U.S. Food and Drug Administration (FDA) gra ...

Company Achieves Record ARR in December, Representing a 300% Increase Over the Past 12 Months Fort Lauderdale, FL, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Algorhythm Holdings, Inc. ("Algorhythm") (NASDAQ: RIME) – a leading AI technology company, announced today that achieved an annualized revenue run rate ("ARR") of $9.7 million during December 2025, representing a 300% increase over the $2.5 million ARR that the company reached at the end of 2024. Current Clients & Market Coverage: In the Indian metropolitan reg ...

HERNDON, Va., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Navient (Nasdaq: NAVI) will host an audio webcast to review its 2025 fourth quarter and year-end financial results on Wednesday, Jan. 28, 2026, at 8:00 a.m. Eastern Time. The webcast will be available on Navient.com/investors; a replay of the webcast will be available on the site. The results and presentations slides will be available the same day by 7:00 a.m. on Navient.com/investors. In addition to being available on the company’s investor website, the resul ...

First data on blood-based mRNA signature for pancreatic ductal adenocarcinoma (PDAC) detection and intraductal papillary mucinous neoplasms (IPMN) differentiation to be presented in San DiegoBERKELEY, Calif. and , Jan. 14, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce its participation in the upcoming American Association for Cancer Research (AACR) 2026 Annual Meeting. This prestigious ...

Core Viewpoint - Jet.AI Inc. has announced an extension of the merger agreement with flyExclusive to April 30, 2026, with the closing expected in the first quarter of 2026 [1] Group 1: Company Overview - Jet.AI Inc. is a technology-driven company focused on deploying artificial intelligence tools and infrastructure to enhance decision-making, efficiency, and performance across complex systems [2] - The company is listed on the NASDAQ Capital Market under the ticker symbol "JTAI" [2] Group 2: Merger Details - The merger agreement between Jet.AI and flyExclusive was originally dated May 6, 2025, and has been amended [3] - flyExclusive has filed a Registration Statement on Form S-4 to register shares of its common stock that will be issued in connection with the proposed transactions [3] Group 3: Statements from Executives - Jet.AI's Founder and Executive Chairman, Mike Winston, expressed excitement and commitment to the merger deal [2] - flyExclusive's Founder and CEO, Jim Segrave, also stated their enthusiastic commitment to the deal [2]

Special closed-ended type private equity investment company INVL Technology, legal entity code 300893533, the registered address Gyneju str. 14 Vilnius, Lithuania (hereinafter – “the Company” or “ INVL Technology”), informs that on the initiative and decision of the management company UAB „INVL Asset Management“ (hereinafter – “the Management Company“), the Extraordinary General Shareholders Meeting (hereinafter – “the Meeting”) is to be held on 5 February 2026. The place of the Meeting: the office of the ...

INVL Technology (hereinafter – “the Company”) announces its decision to call an extraordinary general meeting of shareholders at which draft resolutions on extending the Company’s term of operations and related amendments to its Articles of Association will be submitted for consideration. The Company’s current Articles of Association set out that the Company’s term of operations shall continue until 14 July 2026, with the possibility of extending that term for a period of up to 2 (two) years. It will be pro ...

Core Insights - Intuitive announced preliminary financial results for Q4 and full year 2025, highlighting significant revenue growth driven by increased procedure volume and system placements [1][3][10] Financial Performance - Q4 2025 revenue is expected to be approximately $2.87 billion, a 19% increase from $2.41 billion in Q4 2024 [3] - Full year 2025 revenue is projected at approximately $10.06 billion, reflecting a 21% increase compared to $8.35 billion in 2024 [3] - Instruments and accessories revenue for Q4 2025 increased by 17% to approximately $1.66 billion, up from $1.41 billion in Q4 2024, driven by an 18% growth in worldwide procedure volume [4] - Full year 2025 instruments and accessories revenue rose by 19% to approximately $6.02 billion, compared to $5.08 billion in 2024 [4] Procedure Volume - Q4 2025 da Vinci procedures increased by approximately 17% compared to Q4 2024, with a total of about 3,153,000 procedures performed in 2025, an 18% increase from approximately 2,683,000 in 2024 [5] - Growth in da Vinci procedure volume was largely due to an 18% increase in U.S. general surgery procedures and a 23% increase in procedures performed outside the U.S. [5] - Worldwide da Vinci procedures are expected to grow by approximately 13% to 15% in 2026 [5] System Placements - In Q4 2025, the company placed 532 da Vinci surgical systems, compared to 493 in Q4 2024, including 303 da Vinci 5 systems [6][8] - For the full year 2025, 1,721 da Vinci surgical systems were placed, an increase from 1,526 in 2024, with 870 being da Vinci 5 systems [9] Revenue Breakdown - Q4 2025 systems revenue was approximately $786 million, up from $655 million in Q4 2024, attributed to increased system placements and higher average selling prices [6][7] - Full year 2025 systems revenue reached approximately $2.47 billion, compared to $1.97 billion in 2024 [7] Company Outlook - CEO Dave Rosa expressed satisfaction with the company's performance, noting increased adoption and utilization of surgical platforms and over 3.1 million da Vinci procedures performed in 2025 [10] - The company is scheduled to present detailed financial results at the J.P. Morgan Healthcare Conference on January 14, 2026 [11]

MONTREAL, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQX: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products at affordable prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., is pleased to announce that it has qualified to have its common shares quoted for trading on the OTCQX Best Market (“OTCQX“). Cannara’s common shares were previously quoted on the OTCQB Venture Market. ...